Search results
Showing 16 to 30 of 83 results for colitis
Summary of the evidence on the antimicrobial prescribing of ceftolozane with tazobactam for hospital-acquired pneumonia, including ventilator-associated
Evidence-based recommendations on secukinumab (Cosentyx) for treating active ankylosing spondylitis that has not responded well enough to conventional therapy.
This quality standard covers diagnosing and managing inflammatory bowel disease (Crohn’s disease and ulcerative colitis) in adults, young people and children. It describes high-quality care in priority areas for improvement.
Evidence-based recommendations on therapeutic monitoring of tumour necrosis factor (TNF)-alpha inhibitors (LISA-TRACKER, IDKmonitor and Promonitor ELISA kits) in people with Crohn’s disease
Find out more about the NICE technology appraisal advisory committee B members and their registered interests
Evidence-based recommendations on etrasimod (Velsipity) for moderately to severely active ulcerative colitis in people aged 16 and over.
Infliximab for acute exacerbations of ulcerative colitis (TA163)
Evidence-based recommendations on infliximab (Remicade) for treating acute exacerbations of severely active ulcerative colitis in adults.
Upadacitinib for treating moderately to severely active ulcerative colitis (TA856)
Evidence-based recommendations on upadacitinib (Rinvoq) for treating moderately to severely active ulcerative colitis in adults.
Ozanimod for treating moderately to severely active ulcerative colitis (TA828)
Evidence-based recommendations on ozanimod (Zeposia) for treating moderately to severely active ulcerative colitis in adults when conventional or biological treatments cannot be tolerated or are not working well enough.
Tofacitinib for moderately to severely active ulcerative colitis (TA547)
Evidence-based recommendations on tofacitinib (Xeljanz) for previously treated moderately to severely active ulcerative colitis in adults.
Vedolizumab for treating moderately to severely active ulcerative colitis (TA342)
Evidence-based recommendations on vedolizumab (Entyvio) for treating moderate to severe ulcerative colitis in adults.
Clostridium difficile infection: risk with broad-spectrum antibiotics (ESMPB1)
Summary of the evidence on the risk of using broad-specturm antibiotics associated with clostridium difficile infection
Risankizumab for treating moderately to severely active ulcerative colitis (TA998)
Evidence-based recommendations on risankizumab (Skyrizi) for treating moderately to severely active ulcerative colitis in adults.
Filgotinib for treating moderately to severely active ulcerative colitis (TA792)
Evidence-based recommendations on filgotinib (Jyseleca) for moderately to severely active ulcerative colitis in adults when conventional or biological treatment cannot be tolerated, or the disease has responded inadequately or lost response to treatment.
Guselkumab for treating moderately to severely active ulcerative colitis (TA1094)
Evidence-based recommendations on guselkumab (Tremfya) for treating moderately to severely active ulcerative colitis in adults.